NIKKEI 225
29,226.86 +201.40 (+0.69%) HANG SENG
25,409.75 +447.15 (+1.79%) GOLD FUTURES
1,766.30 +0.60 (+0.03%) DOW
35,258.61 -36.15 (-0.10%) BTC-GBP
45,269.75 -208.63 (-0.46%) CMC Crypto 200
1,449.31 -2.32 (-0.16%)
Galapagos NV (GLPG.AS)
| Previous close | 46.14 |
| Open | 45.92 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 44.21 - 46.04 |
| 52-week range | 42.07 - 115.00 |
| Volume | 343,653 |
| Avg. volume | 369,650 |
| Market cap | 2.909B |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.69 |
| Earnings date | 04 Nov 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study
Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.
- Globe Newswire
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
Continuing filgotinib 200mg among induction non-responders at week 10 resulted in clinical benefits for ulcerative colitis (UC) patients in the long-term extension study (LTE)Treatment with filgotinib 200mg resulted in clinically meaningful improvements in health-related quality of life (HRQoL) measures by week 58 among patients with UC Mechelen, Belgium; 4 October 2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced results of two post-hoc analyses from the SELECTION and SELE
- Globe Newswire
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
1,374 patients enrolled into the phase 3 study across 369 global sitesTopline data anticipated in H1 2023Galapagos will assume responsibility for the DIVERSITY study Mechelen, Belgium; 4 October 2021, 07.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced randomization of the last patient into the multi-center, global DIVERSITY Phase 3 study. The study is designed to evaluate the efficacy and safety of filgotinib, a JAK1 preferential inhibitor, in the induction and maintenance of remi
